Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference
04 mai 2022 13h30 HE
|
Editas Medicine, Inc.
Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels Treated eyes showed morphological and functional...
Editas Medicine Announces First Quarter 2022 Results and Business Updates
04 mai 2022 06h45 HE
|
Editas Medicine, Inc.
Appointed Gilmore O’Neill as CEO effective June 1, 2022; James C. Mullen to serve as Executive Chairman First pediatric patient dosed in Phase 1/2 BRILLIANCE trial of EDIT-101 for LCA10; clinical...
Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting
02 mai 2022 16h31 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for presentation,...
Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update
27 avr. 2022 06h55 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia
26 avr. 2022 09h00 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA)...
Editas Medicine Appoints Gilmore O’Neill as Chief Executive Officer
14 avr. 2022 07h30 HE
|
Editas Medicine, Inc.
James C. Mullen to Serve as Executive Chairman CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that its...
Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10
11 avr. 2022 09h00 HE
|
Editas Medicine, Inc.
Marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient Company on track to complete dosing of the pediatric mid-dose cohort in the first...
Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting
08 avr. 2022 13h00 HE
|
Editas Medicine, Inc.
Preclinical data demonstrate that edited iNK cells result in increased persistence, enhanced anti-tumor activity and extended survival supporting continued development as a novel therapeutic approach...
Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference
28 févr. 2022 16h01 HE
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued...
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates
24 févr. 2022 06h30 HE
|
Editas Medicine, Inc.
EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022 EDIT-301 remains on track to dose first sickle cell disease patient in 1H 2022 and...